Novo Nordisk weight-loss data reveals promising outcomes for new treatments, boosting investor confidence and leading to stock price increases.
Read More

Novo Nordisk weight-loss data reveals promising outcomes for new treatments, boosting investor confidence and leading to stock price increases.
Read MoreInovio stock rise highlights the impact of plasmid DNA drug approval on market performance.
Read More
FDA approval for SMA marks a significant milestone in treating muscle loss.
Read More